Table 2.
Summary of the CAR-T cells modified with gene editing.
| CAR | Gene-editing method | Targeted gene | Gene editing efficiency (%) | Malignancy | Reference |
|---|---|---|---|---|---|
| KNOCK-OUT | |||||
| CD19 scFv/4-1BB/CD3ζ | Cas9 RNP electroporation | TRAC | 85 | B cell acute lymphoblastic leukemia | (41, 42) |
| β2M | 100 | ||||
| PD-1 | 64.7 | ||||
| CD19 scFv/4-1BB/CD3ζ | Cas9 RNP electroporation | TRAC | 81.7 | B cell acute lymphoblastic leukemia | (45) |
| TRBC | 49.3 | ||||
| β2M | 79.9 | ||||
| CD7 scFv/CD28/4-1BB//CD3ζ | Cas9 RNP electroporation | CD7 | 89.14 | T cell acute lymphoblastic leukemia | (44, 52) |
| EBV-LMP2A CTL | Cas9 plasmid electroporation | PD-1 | 47.4 | Epstein-Barr virus-associated gastric cancer | (46) |
| CD19 scFv/4-1BB/CD3ζ | Cas9 RNP electroporation | LAG-3 | 45–70 | B cell acute lymphoblastic leukemia | (47) |
| KNOCK-IN | |||||
| CD19 scFv/4-1BB/CD3ζ | Cas9 RNP electroporation and transfection with AAV6 encoding CAR | TRAC exon 1 | 50 | B cell lymphoma | (48) |
| CD19 scFv/CD28/CD3ζ | Cas9 RNP electroporation and transfection with AAV encoding CAR | TRAC exon1 | 40 | Adult B acute lymphoblastic leukemia | (49) |